Key facts
- Rohto Pharmaceutical plans clinical trials in Hong Kong, the report said.
- Rohto is the first Japanese company to partner with Hong Kong under the OASES initiative, the report said.
- Rohto is among 18 firms in the latest OASES intake, the report said.
Japanese drug maker Rohto Pharmaceutical plans to conduct clinical trials in Hong Kong, making it the first company from Japan to partner with the city's government under a flagship investment initiative, according to a report that did not date the event.
Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), the report said. The company was drawn by top university research, cross-border data exchanges and access to mainland China's large market.
The report did not state the value of Rohto's investment, the timing of the trials or the terms of the partnership.